In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration

AAPS PharmSciTech

Volumn 11, Issue 1, 2010, Pages 85-89

  Nasr, Mohamed ^a  

^a Ein Helwan   (Egypt)

Author keywords

Bioavailability; Celecoxib; Proniosomes

Indexed keywords

CELECOXIB; CHOLESTEROL; DICETYL PHOSPHATE; DRUG CARRIER; NIOSOME; PRONIOSOME; SORBITAN STEARATE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; HEXOSES; HUMANS; LIPOSOMES; PHOSPHORIC ACID ESTERS; POWDERS; PYRAZOLES; SULFONAMIDES;

EID: 77950916622     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9364-5     Document Type: Article

References (25)

1. GS Geis 1999 Update on clinical development with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol 28 31 37 10.1080/030097499750042407 Suppl
2. LS Simon FL Lanza PE Lipsky 1998 Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor Arthritis Rheum 41 1591 1602 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J 1:CAS:528:DyaK1cXmsVChtbk%3D 9751091 (Pubitemid 28459917)
3. E Tindall 1999 Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results J Am Osteopath Assoc 99 S13 S17 1:STN:280:DC%2BD3c7gslOrug%3D%3D 10643176
4. SK Paulson JD Hribar NW Liu EJ Hajdu RH Bible A Piergies A Karim 2000 Metabolism and excretion of celecoxib in healthy male volunteers Drug Metab Dispos 28 308 314 1:CAS:528:DC%2BD3cXhsVOitr0%3D 10681375
5. SK Paulson MB Vaughn SM Jessen Y Lawal CJ Gresk B Yan TJ Maziasz CS Cook A Karim 2001 Pharmacokinetics of celecoxib after oral administration in dogs and humans; effect of food and site of absorption J Pharmacol Exp Ther 297 2 638 645 1:CAS:528:DC%2BD3MXjt1Wlsbw%3D 11303053
6. Neelam S, Sonu B. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003;4(3):Article 33.
7. Narender R, Tasneem R, Ramakrishna S, Chowdary K, Prakash V. Β-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSciTech. 2004;6(1):Article 7.
8. MS Nagarsenker MS Joshi 2005 Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage Drug Dev Ind Pharm 31 2 169 178 10.1081/DDC-200047795 1:CAS:528:DC%2BD2MXit1Srsr4%3D 15773284 (Pubitemid 40315712)
9. R Dixit M Nagarsenker 2007 In vitro and in vivo advantage of celecoxib surface solid dispersion and dosage form development Indian J Pharm Sci 69 3 370 377 10.4103/0250-474X.34545 1:CAS:528:DC%2BD1MXhtVGqs7fP (Pubitemid 47379264)
10. VR Gupta S Mutalik MM Patel GK Jani 2007 Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties Acta Pharm. 57 2 173 184 10.2478/v10007-007-0014-8 1:CAS:528:DC%2BD2sXls1ygtb0%3D 17507314 (Pubitemid 46761981)
11. HR Guzman M Tawa Z Zhang P Ratanabanangkoon P Shaw CR Gardner H Chen JP Moreau O Almarsson JF Remenar 2007 Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J Pharm Sci 96 10 2686 2702 10.1002/jps.20906 1:CAS:528: DC%2BD2sXhtFKrtLbJ 17518357 (Pubitemid 47597818)
12. Javed A, Shweta A, Alka A, Anil K, Rakesh K, Roop K. Formulation and development of floating capsules of celecoxib: in vitro and in vivo evaluation. AAPS PharmSciTech. 2007;8(4):Article 119.
13. T Angel S Spomenka K Andrew R Thomas A Clive 2009 Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs J Control Release 134 62 70 10.1016/j.jconrel.2008.10.014
14. MN Azmin AT Florence RM Handjani-Vila FB Stuart G Vanlerberghe JS Whittaker 1985 The effects of nonionic surfactant vesicles (niosomes) entrapment on the absorption and distribution of methotrexate in mice J Pharm Pharmacol 37 237 242 1:CAS:528:DyaL2MXit1GqtLc%3D 2860220
15. AJ Baillie AT Florence LR Hume GT Muirhead A Rogerson 1985 The preparation and properties of niosomes-non-ionic surfactant vesicles J Pharm Pharmacol. 37 863 868 1:CAS:528:DyaL28XhtVGhuw%3D%3D 2868092
16. A Namdeo NK Jain 1999 Niosomal delivery of 5-fluorouracil J Microencapsul 16 731 740 10.1080/026520499288672 1:CAS:528:DyaK1MXmvFehu7g%3D 10575625 (Pubitemid 29478952)
17. AI Blazek-Welsh DG Rhodes 2001 SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes Pharm Res 18 656 661 10.1023/A:1011037527889 1:CAS:528:DC%2BD3MXltVKmtLk%3D 11465422 (Pubitemid 32595795)
18. C Hu DG Rhodes 1990 Proniosomes: a novel drug carrier preparation Int J Pharm 185 23 35 10.1016/S0378-5173(99)00122-2
19. Kora PR, Sekuboyina VS. Influence of hydrophilic polymer on celecoxib complexation with hydroxypropyl β-cyclodextrin. AAPS PharmSciTech 2006;7(3):Article 79.
20. Gilbaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982. p. 409-17.
21. Shargel L, Wu-pong S, Yu A. Applied biopharmaceutics & pharmacokinetics. 5th ed. the McGraw-Hill Companies; 2005;171-3.
22. V Bhavana JK Ajay NK Jain 1998 Proniosome based transdermal delivery of levonorgestrel for effective contraception J Control Release 54 149 165 10.1016/S0168-3659(97)00100-4 (Pubitemid 28342694)
23. M Raymond M Josbert H Marcel P Adriënne M Grietje S Gert 2005 Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice Neoplasia 7 2 118 127 10.1593/neo.04340 (Pubitemid 40315989)
24. GV Betageri 1993 Liposomal encapsulation and stability of dideoxyinosine triphosphate Drug Dev Ind Pharm 19 532 539
25. Y Xiao Y Song Z Chen Q Ping 2006 Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs Int J Pharm 319 162 168 10.1016/j.ijpharm.2006.03.037 1:CAS:528:DC%2BD28XmvFKgu7Y%3D (Pubitemid 44051803)